Intended for UK healthcare professionals only

Adverse Event Reporting can be found on the final page of this document. Click here for Prescribing Information.

Exeltis
Rethinking healthcare

Life is complicated...



...HRT doesn't have to be

femoston®
estradiol/dydrogesterone

Femoston® is indicated for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses and Femoston®-conti is indicated for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses[1-4].

Femoston® advantages

femoston®
estradiol/dydrogesterone

Well-Balanced Oestrogen and Progestogen Combination

Femoston® contains oestradiol (a body identical oestrogen, structurally identical to endogenous oestrogen) and dydrogesterone, a progestogen with fewer androgenic or metabolic side effects compared to older ones like norethisterone.[1,4,5]

Suitable for Perimenopausal and Menopausal Women

The Femoston® range is available in sequential combined (Femoston®) and continuous combined preparations (Femoston®-conti) covering a wide range of doses (standard to ultra-low).[1-4]

Cardiovascular Risk

Femoston® is not associated with a higher risk of cardiovascular events than use of other HRT.[6]

Bleeding Control

The percentage of women with amenorrhoea increased from 81.1% and 74.6% at 3 months to 91.4% and 88.2% in months 10-12 in women receiving E 0.5mg/D 2.5mg and E 1mg/D 5mg, respectively compared to placebo (81.5%). N=313[7]

Osteoporosis Prevention

Femoston®-conti 1mg/5mg, Femoston® 1/10mg and 2/10mg film-coated tablets are also indicated for the prevention of osteoporosis in postmenopausal women.[1,2,4]

Once-Daily Dosing Convenience

Convenience of once-daily, fixed oral dose preparation.[1-4]

Endometrial Protection

Femoston® has been shown to provide effective endometrial protection with an acceptable bleeding and tolerability profile.[8-10]

Vasomotor Symptom Control

Femoston®-conti has been shown to have effective vasomotor symptom control compared to placebo. Both Femoston®-conti 0.5/2.5mg and 1/5mg were well tolerated.[7] (Full analysis sample, n=305).

Breast Cancer & VTE Risk

Dydrogesterone is associated with a lower breast cancer and VTE risk compared to other synthetic progestogens.[11-13*]

*Norethisterone acetate (NETA), Medroxyprogesterone acetate (MPA), (levo)norgesterol

The Femoston® Range

Supporting women throughout the menopause transition and beyond

Sequential

For oestrogen deficiency symptoms in postmenopausal women at least 6 months after last menses[1-2].

femoston®
estradiol / dydrogesterone
1mg/10mg

femoston®
estradiol / dydrogesterone
2mg/10mg

Continuous

For oestrogen deficiency symptoms in postmenopausal women at least 12 months after last menses[3-4].

femoston®*-conti*
estradiol / dydrogesterone
1mg/5mg

femoston®*-conti*
estradiol / dydrogesterone
0.5mg/2.5mg

Ultra low dose

Ultra low dose

1. Femoston® 1mg/10mg SmPC
2. Femoston® 2/10mg SmPC
3. Femoston®-conti 0.5mg/2.5mg SmPC
4. Femoston®-conti 1mg/5mg SmPC
5. Binkowska M and Woron J. Prz Menopauzalny 2015 Jun 22;14(2):134–143
6. Schneider C et al. Clinacteric. 2009;12(5):445–453
7. Stevenson JC, et al. Maturitas. 2010;67(3):227–232 Available from https://www.nice.org.uk/guidance/ng23 [Accessed September 2025]
8. Ferenczy A et al. Climacteric 2002; 5(1):26–35
9. Quereux C et al. Maturitas. 2006; 53(3):299–305
10. Bergeron C et al. Maturitas. 2010; 66(2):201–205
11. Fournier A et al. Breast Cancer Res Treat. 2008;107:103–11
12. Baber RJ et al. IMS Writing Group. Climacteric. 2016;19(2):109-50
13. Collaborative Group on Hormonal Factors in Breast Cancer. The Lancet. 2019; 394(10204):1159–1168

EXE-E/IPR-FEM-2372-v1 | October 2025

femoston®
estradiol/dydrogesterone